AT1 FY21 - General Discussion + FA, page-1758

yes, I agree its more likely to be a timing issue for Ab tests. Its just the negative perception that it conveys to the general market - that AT1's device IP is unique enough but doesn't seem to sell beyond the initial contract excitement. AT1 still has to land a regular OEM supply arrangement despite being a proven platform for Ab tests, pregnancy, HIV etc

What also is surprising is that despite the NG Bio take-up failure (for their Ab test) Access Bio went the same route and locked themselves into this take/pay deal in 2020...it seems to indicate they also got US Ab test timing incorrect OR the Ab revolution is not happening much? US vaccinations are much further ahead (overall) compared to AU + Access Bio also sells into Central/South America/SE Asia geos too...all of which are potential Ag+Ab test package markets and should have easily chewed up the 2m initial qty.

For sure, contracts can be re-negotiated or the Ab timing could become better later on..lets see what AT1 says today and in next qtrly. In the end AT1 will at least get rev for the 2m devices, so some cash in the bank at least..